Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.69−0.02 (-0.54%)
Close on Nov 20, 2026Market cap $281.54MP/E –Yield –
Fulcrum Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Fulcrum Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$66.14M. For fiscal 2025 it was -$60.38M. The highest annual figure on record is -$2.50M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.38M | – |
| FY2024 | Dec 31, 2024 | -$2.50M | – |
| FY2023 | Dec 31, 2023 | -$91.47M | – |
| FY2022 | Dec 31, 2022 | -$99.01M | – |
| FY2021 | Dec 31, 2021 | -$80.19M | – |
| FY2020 | Dec 31, 2020 | -$55.00M | – |
| FY2019 | Dec 31, 2019 | -$40.34M | – |
| FY2018 | Dec 31, 2018 | -$31.54M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.89M | -123.6% |
| Q1 FY2025 | Mar 31, 2025 | -$15.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.09M | – |
| Q2 FY2024 | Jun 30, 2024 | $58.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.98M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.17M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.68M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.35M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.33M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.77M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.60M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.30M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.21M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.87M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.05M | – |
See a number that looks wrong?